COMMISSION IMPLEMENTING REGULATION (EU) 2025/2233

| Official Journal of the European Union | EN L series ---|---|--- * * * | 2025/2233 | 7.11.2025 ---|---|--- COMMISSION IMPLEMENTING REGULATION (EU) 2025/2233 of 6 November 2025 authorising the placing on the market of Clostridium butyricum TO-A as a novel food and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (1), and in particular Article 12(1) thereof, Whereas: (1) | Regulation (EU) 2015/2283 provides that only novel foods authorised and included in the Union list of novel foods may be placed on the market within the Union. ---|--- (2) | Pursuant to Article 8 of Regulation (EU) 2015/2283, Commission Implementing Regulation (EU) 2017/2470 (2) has established a Union list of novel foods. ---|--- (3) | On 10 November 2021, the company TOA Biopharma Co. Ltd. (‘the applicant’) submitted an application for an authorisation to the Commission in accordance with Article 10(1) of Regulation (EU) 2015/2283 to place Clostridium butyricum TO-A on the Union market as a novel food. The applicant requested for the novel food to be used in food supplements as defined in Directive 2002/46/EC of the European Parliament and of the Council (3), for the general population above 3 months of age. ---|--- (4) | On 10 November 2021, the applicant also made a request to the Commission for the protection of the following proprietary data: manufacturing process (4), nutritional analysis (part 1–5) (5), C. butyricum analysis (part 1–5) (6), purity analysis (part 1–5) (7), AMES study (8), micronucleus study (9), AMES supernatant study (10), micronucleus supernatant study (11), in vivo micronucleus comet supernatant study (12), Lysis efficiency French Press study (13), Appendix1 SEM images (14), AMES Lysate study (15), micronucleus Lysate study (16) and subchronic toxicity study (17). ---|--- (5) | On 8 June 2022, the Commission requested the European Food Safety Authority (‘the Authority’) to provide a scientific opinion on Clostridium butyricum TO-A as a novel food. ---|--- (6) | On 25 March 2025, the Authority adopted its scientific opinion on the ‘Safety of Clostridium butyricum TO-A as a novel food pursuant to Regulation (EU) 2015/2283’ (18) in accordance with Article 11 of Regulation (EU) 2015/2283. ---|--- (7) | Taking into account that the applicant requested the novel food to be used in food supplements as defined in Directive 2002/46/EC, for the general population above 3 months of age, the Authority indicated in its opinion that the target population for the novel food should be restricted to children above 3 years of age, adolescents and adults, excluding pregnant and lactating women. This was based on the consideration that appropriate initial bacteria colonisation of the gastrointestinal tract in humans, in particular during the first 3 years of life, profoundly affects health during infancy and childhood, that little is known on how the maternal microbiota shapes the maternal-fetal immune system during pregnancy, that disruptions to the microbiota early in life can have lasting health effects into adulthood and taking into account that the 90-day oral toxicity study was conducted in adult rats, which hampers the extrapolation of the results to early life stages in humans. ---|--- (8) | In its scientific opinion, the Authority concluded that Clostridium butyricum TO-A is safe at 1,0 × 108 CFU/day for children (3 to < 10 years), 2,0 × 108 CFU/day for adolescents from 10 to < 14 years, 2,8 × 108 CFU/day for adolescents from 14 to < 18 years, and 3,2 × 108 CFU/day for adults, excluding pregnant and lactating women. Therefore, that scientific opinion gives sufficient grounds to establish that Clostridium butyricum TO-A, when used not exceeding those levels in food supplements, fulfils the conditions for its placing on the market in accordance with Article 12(1) of Regulation (EU) 2015/2283. ---|--- (9) | In its scientific opinion, the Authority also noted that its conclusion on the safety of the novel food was based on the proprietary data on the manufacturing process, nutritional analysis (part 1–5), C. butyricum analysis (part 1–5), purity analysis (part 1–5), AMES study, micronucleus study, AMES supernatant study, micronucleus supernatant study, in vivo micronucleus comet supernatant study, Lysis efficiency French Press study, Appendix1 SEM images, AMES Lysate study, micronucleus Lysate study and subchronic toxicity study, without which it could not have assessed the novel food and reached its conclusion. ---|--- (10) | The Commission requested the applicant to further clarify the justification provided with regard to its proprietary claim over those data and studies and to clarify their claim to an exclusive right of reference to them in accordance with Article 26(2), point (b), of Regulation (EU) 2015/2283. ---|--- (11) | The applicant declared that they held proprietary and exclusive rights of reference to the relevant studies, at the time they submitted the application, and that third parties cannot lawfully access, use or refer to those data. ---|--- (12) | The Commission assessed all the information provided by the applicant and considers that they have sufficiently substantiated the fulfilment of the requirements laid down in Article 26(2) of Regulation (EU) 2015/2283. Therefore, data on the manufacturing process, nutritional analysis (part 1–5), C. butyricum analysis (part 1–5), purity analysis (part 1–5), AMES study, micronucleus study, AMES supernatant study, micronucleus supernatant study, in vivo micronucleus comet supernatant study, Lysis efficiency French Press study, Appendix1 SEM images, AMES Lysate study, micronucleus Lysate study and subchronic toxicity study, should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283. Accordingly, only the applicant should be authorised to place Clostridium butyricum TO-A on the market within the Union during a period of five years from the entry into force of this Regulation. ---|--- (13) | However, such restriction of the authorisation and the reference to the data contained in the applicant’s file for their sole use does not prevent subsequent applicants from applying for an authorisation to place on the market the same novel food provided that their application is based on legally obtained information supporting such an authorisation. ---|--- (14) | It is appropriate that the inclusion of Clostridium butyricum TO-A as a novel food in the Union list of novel foods contains the information referred to in Article 9(3) of Regulation (EU) 2015/2283. In line with the conditions of use of food supplements containing Clostridium butyricum TO-A as proposed by the applicant, it is necessary to inform the consumers in that regard by appropriate labelling about the uses of food supplements containing Clostridium butyricum TO-A. ---|--- (15) | Clostridium butyricum TO-A should be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470. The Annex to Implementing Regulation (EU) 2017/2470 should therefore be amended accordingly. ---|--- (16) | The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed, ---|--- HAS ADOPTED THIS REGULATION: Article 1 1\. Clostridium butyricum TO-A is authorised to be placed on the market within the Union. Clostridium butyricum TO-A shall be included in the Union list of novel foods set out in Implementing Regulation (EU) 2017/2470. 2\. The Annex to Implementing Regulation (EU) 2017/2470 is amended in accordance with the Annex to this Regulation. Article 2 Only the company TOA Biopharma Co. Ltd. (19) is authorised to place on the market within the Union the novel food referred to in Article 1, for a period of 5 years from 27 November 2025, unless a subsequent applicant obtains an authorisation for the novel food without reference to the scientific data protected pursuant to Article 3 or with the agreement of the company TOA Biopharma Co. Ltd. Article 3 The scientific data contained in the application file and fulfilling the conditions laid down in Article 26(2) of Regulation (EU) 2015/2283 shall not be used for the benefit of a subsequent applicant for a period of 5 years from the date of entry into force of this Regulation without the agreement of the company TOA Biopharma Co. Ltd. Article 4 This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union. This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 6 November 2025. For the Commission The President Ursula VON DER LEYEN * * * (1) OJ L 327, 11.12.2015, p. 1, ELI: http://data.europa.eu/eli/reg/2015/2283/oj. (2) Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351, 30.12.2017, p. 72, ELI: http://data.europa.eu/eli/reg_impl/2017/2470/oj). (3) Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ L 183, 12.7.2002, p. 51, ELI: http://data.europa.eu/eli/dir/2002/46/oj). (4) Annex_I_2_1_1 to the application. (5) Annex_l_3_1_1 to the application. (6) Annex_l_3_1_2 to the application. (7) Annex_l_3_1_3 to the application. (8) Annex_l_9_2_1 to the application. (9) Annex_l_9_2_2 to the application. (10) Annex_l_9_2_3 to the application. (11) Annex_l_9_2_4 to the application. (12) Annex_l_9_2_5 to the application. (13) Annex_l_9_2_6 to the application. (14) Annex_l_9_2_6 to the application. (15) Annex_l_9_2_7 to the application. (16) Annex_l_9 _2_8 to the application. (17) Annex_l_9_3 to the application. (18) EFSA Journal. 2025;23:e9371. (19) Address: 2-1-11, Sasazuka, Shibuya, Tokyo, Japan. * * * ANNEX The Annex to Implementing Regulation (EU) 2017/2470 is amended as follows: (1) | In Table 1 (Authorised novel foods) the following entry is inserted: | Authorised novel food | Conditions under which the novel food may be used | Additional specific labelling requirements | Other requirements | Data protection ---|---|---|---|--- ‘ Clostridium butyricum TO-A | Specified food category | Maximum levels | | 1. | The designation of the novel food on the labelling of the foodstuffs containing it shall be ‘Clostridium butyricum TO-A’. ---|--- 2. | The labelling of food supplements containing Clostridium butyricum TO-A shall bear a statement that the food supplements should not be consumed by: | a) | pregnant and lactating women ---|--- b) | infants and children under 3 years of age ---|--- c) | infants and children under 10 years of age ---|--- d) | infants and children under 14 years of age ---|--- e) | infants, children and adolescents under 18 years of age depending on the age group the food supplements is intended for. ---|--- | Authorised on 27 November 2025. This inclusion is based on proprietary scientific evidence and scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283. Applicant: TOA Biopharma Co. Ltd., 2-1-11, Sasazuka, Shibuya, Tokyo, Japan. During the period of data protection, the novel food Clostridium butyricum TO-A is authorised for placing on the market within the Union only by TOA Biopharma Co. Ltd., unless a subsequent applicant obtains authorisation for the novel food without reference to the proprietary scientific evidence or scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283 or with the agreement of TOA Biopharma Co. Ltd. End date of the data protection: 27 November 2032’ Food supplements as defined in Directive 2002/46/EC, excluding infants and young children, and pregnant and lactating women | 1,0 × 108 CFU/day for children from 3 to < 10 years 2,0 × 108 CFU/day for adolescents from 10 to < 14 years 2,8 × 108 CFU/day for adolescents from 14 to < 18 years 3,2 × 108 CFU/day for adults, excluding pregnant and lactating women (2) | in Table 2 (Specifications), the following entry is inserted: | Authorised Novel Food | Specifications ---|--- ‘ Clostridium butyricum TO-A | Description/Definition Clostridium butyricum TO-A, is a gram-positive, spore-forming, obligate anaerobic, non-pathogenic, non-genetically modified bacterium. The TO-A strain is deposited under number FERM BP-10866. The novel food is produced by anaerobic fermentation of Clostridium butyricum TO-A followed by centrifugation and spray-drying and mixed with potato starch (to stabilise the spores by keeping a dry environment). The novel food is a mixture of viable spores and vegetative cells with about 85 % (range: 74 %–89 %) of spores. Characteristics/criteria C. butyricum TO-A: 1-7 × 109 CFU/g Moisture: < 5 % Coliforms: < 10 CFU/g TAMC: ≤ 1 × 103 CFU/g TYMC: ≤ 1 × 102 CFU/g Salmonella spp.: not detected in 25 g Abbreviations: CFU, colony forming units; TAMC, total aerobic microbial count; TYMC, total yeast and mould count.’ * * * ELI: http://data.europa.eu/eli/reg_impl/2025/2233/oj ISSN 1977-0677 (electronic edition) * * *